Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the RP2D of 1.8 mg/m(2). Using a single-stage design, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H. J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J. C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, Zwaan, Christian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162924/
https://www.ncbi.nlm.nih.gov/pubmed/35468945
http://dx.doi.org/10.1038/s41375-022-01576-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162924/
https://www.ncbi.nlm.nih.gov/pubmed/35468945
http://dx.doi.org/10.1038/s41375-022-01576-3

Ejemplares similares